Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions

Abstract

Get full access to this article

View all access options for this article.

References

Rothman

Greenland

Lash

TL.

Modern Epidemiology. 3rd ed. Philadelphia, PA: Wolters Kluwer Health/ Lippincott Williams & Wilkins, 2008.

Strom

. Pharmacoepidemiology. 4th ed. New York: Wiley, 2005.

Banwell

Bar-Or

Arnold

. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 2011; 10: 436–445.

MedWatch. FDA Drug Safety Communication: Safety update on Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab). Updated 22 April 2011, http://www.fda.gov/Drugs/DrugSafety/ucm252045.htm (accessed 28 April 2011).

Ellis

Boggild

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

Mult Scler 2009; 15: 505–508.

Ramagopalan

Dyment

Valdar

. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007; 6: 604–610.

Ascherio

Zhang

Hernan

. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327–332.

Renoux

Suissa

Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol 2008; 64: 109-110; author reply 10.

Alonso-Magdalena

Romero-Pinel

Moral

. Anticipation of age at onset in multiple sclerosis: methodologic pitfalls. Acta Neurol Scand 2010; 121: 426–428.

10.

Akl

Oxman

Herrin

. Using alternative statistical formats for presenting risks and risk reductions. Cochrane Database Syst Rev 2011; 16: CD006776.

Epidemiology in multiple sclerosis has had its day: there are no more unanswered questions - No

Abstract

Get full access to this article

References